Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of GSK3888130B in Healthy Participants
NCT05131971Phase 1Completed
- Sponsor
- GSK
- Start
- Nov 2021
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK3888130B in multiple sclerosis (MS) and ulcerative colitis (UC) (14 cohorts), sponsored by GSK. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 160 days, Number of Participants With Clinically Significant Changes in Hematology Results up to 85 days and 8 more. Started Nov 2021; status: completed.
02
Drugs
GSK3888130B
03
Conditions
multiple sclerosis (MS)ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05131971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05131971.